JP5571336B2 - 流体内検体濃度検知方法 - Google Patents
流体内検体濃度検知方法 Download PDFInfo
- Publication number
- JP5571336B2 JP5571336B2 JP2009187909A JP2009187909A JP5571336B2 JP 5571336 B2 JP5571336 B2 JP 5571336B2 JP 2009187909 A JP2009187909 A JP 2009187909A JP 2009187909 A JP2009187909 A JP 2009187909A JP 5571336 B2 JP5571336 B2 JP 5571336B2
- Authority
- JP
- Japan
- Prior art keywords
- fluid
- optical
- light
- detection
- cona
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000012530 fluid Substances 0.000 title claims description 39
- 238000000034 method Methods 0.000 title claims description 37
- 239000012491 analyte Substances 0.000 title claims description 32
- 230000003287 optical effect Effects 0.000 claims description 219
- 238000001514 detection method Methods 0.000 claims description 146
- 230000008859 change Effects 0.000 claims description 45
- 210000003722 extracellular fluid Anatomy 0.000 claims description 36
- 230000005540 biological transmission Effects 0.000 claims description 35
- 238000001228 spectrum Methods 0.000 claims description 17
- 230000004044 response Effects 0.000 claims description 7
- 239000008103 glucose Substances 0.000 description 154
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 149
- 108010062580 Concanavalin A Proteins 0.000 description 136
- 229920002307 Dextran Polymers 0.000 description 44
- 230000027455 binding Effects 0.000 description 34
- 239000003795 chemical substances by application Substances 0.000 description 33
- 239000000126 substance Substances 0.000 description 32
- 239000011324 bead Substances 0.000 description 22
- 230000006870 function Effects 0.000 description 20
- 238000005259 measurement Methods 0.000 description 20
- 239000012528 membrane Substances 0.000 description 19
- 229920005654 Sephadex Polymers 0.000 description 18
- 239000012507 Sephadex™ Substances 0.000 description 17
- 210000001124 body fluid Anatomy 0.000 description 14
- 230000007246 mechanism Effects 0.000 description 14
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 13
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 13
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 13
- 239000010839 body fluid Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 10
- 230000003595 spectral effect Effects 0.000 description 10
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 8
- 238000009792 diffusion process Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000005286 illumination Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000000017 hydrogel Substances 0.000 description 6
- 238000005086 pumping Methods 0.000 description 6
- 229920000856 Amylose Polymers 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000013307 optical fiber Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000001934 delay Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000012447 hatching Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000003607 modifier Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000013626 chemical specie Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- -1 for example Substances 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000012014 optical coherence tomography Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108091006073 receptor regulators Proteins 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/1459—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters invasive, e.g. introduced into the body by a catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0031—Implanted circuitry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
- G01N21/359—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
Description
・ その結合に可逆性があること
・ そのレセプタ又は調整剤との結合で検体を幾ばくかは特定できること
・ そのレセプタ・調整剤間結合の解離定数(Kd値)が適切であり、興味ある検体濃度域内でレセプタ又は調整剤に対し検体が十分結合できること
・ その光学特性調整剤により検知用光共振器にもたらされる光学特性変化が、計測可能なものになること
といった条件を満たすものを包括するよう、拡張することができる。
・ 調整剤がレセプタに対し可逆的に結合すること
・ 調整剤の作用で、光共振器たる検知エリアの光学特性のうち一種類又は複数種類が十分に変化すること
といった条件を満たすものを包括するよう、拡張することができる。
Claims (6)
- 光透過特性と光反射特性を有し複数の要素によって少なくとも部分的に仕切られ少なくとも2つは互いに平行な表面を有する光共振器を検知エリアとして2つ以上の検知エリアを含む反射型光共振器システムを準備するステップと、
光共振器システムの2以上の検知エリアのうち、検体の濃度変化に応じて移動する1以上の調整剤のためのリザーバを有する第1室に配置される第1検知エリアの1以上の光学特性を検知するステップと、
光共振器システムの2以上の検知エリアのうち、流体中の非検体の濃度変化に応じて移動する第1検知エリアのための調整剤とは異なる1以上の調整剤のためのリザーバを有する第2室に配置される第2検知エリアの1以上の光学特性を検知するステップと、
第1検知エリアで検知された光学特性と第2検知エリアでの検知された光学特性とを用い、第1検知エリアで検知された光学特性に及ぼす検体の影響度を光学特性に対する干渉成分である流体内非検体成分の影響度から分離するステップと、
検体の影響度と非検体成分の影響度の間の差に基づいて検体濃度を決定するステップと、
を有する流体内検体濃度検知方法。 - 請求項1記載の流体内検体濃度検知方法であって、検知対象となる光学特性が、各検知エリアからの透過出射光又は反射出射光の強度であり、更に、その強度がピークになるスペクトル位置の偏倚を求めるステップを有する流体内検体濃度検知方法。
- 請求項1記載の流体内検体濃度検知方法であって、
第1検知エリア及び第2検知エリアにおける屈折率の変化を求めるステップを有する流体内検体濃度検知方法。 - 請求項1記載の流体内検体濃度検知方法であって、第1検知エリア及び第2検知エリアにおける吸収率の変化を求めるステップを有する流体内検体濃度検知方法。
- 請求項1記載の流体内検体濃度検知方法であって、既知の基準流体が事前装填されており且つ外部の流体が進入しないように封止されている別の室即ち基準室の検知エリアの光学特性を検知するステップを有する流体内検体濃度検知方法。
- 請求項1記載の流体内検体濃度検知方法であって、その内部に第1検知エリアがある第1室とその内部に第2検知エリアがある第2室とを一体形成又は連結したものを、間質液に接触するよう皮下又は皮膚内に埋め込むステップを有する流体内検体濃度検知方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/195,997 | 2008-08-21 | ||
US12/195,997 US7961326B2 (en) | 2008-08-21 | 2008-08-21 | Method of detecting the concentration of an analyte |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010048807A JP2010048807A (ja) | 2010-03-04 |
JP2010048807A5 JP2010048807A5 (ja) | 2012-09-27 |
JP5571336B2 true JP5571336B2 (ja) | 2014-08-13 |
Family
ID=41323549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009187909A Expired - Fee Related JP5571336B2 (ja) | 2008-08-21 | 2009-08-14 | 流体内検体濃度検知方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US7961326B2 (ja) |
EP (1) | EP2156787B1 (ja) |
JP (1) | JP5571336B2 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8320983B2 (en) * | 2007-12-17 | 2012-11-27 | Palo Alto Research Center Incorporated | Controlling transfer of objects affecting optical characteristics |
JP2010091318A (ja) * | 2008-10-06 | 2010-04-22 | Seiko Epson Corp | 生体内薬剤濃度分布測定装置およびこれに用いる波長可変フィルタ、生体内薬剤濃度分布測定方法 |
WO2010048512A1 (en) * | 2008-10-24 | 2010-04-29 | University Of Notre Dame Du Lac | Methods and apparatus to obtain suspended particle information |
GB201207881D0 (en) * | 2012-05-04 | 2012-06-20 | Isis Innovation | Active chemical sensing using optical microcavity |
US9791376B2 (en) | 2012-06-12 | 2017-10-17 | Panasonic Intellectual Property Management Co., Ltd. | Optical sensor |
JP2014203831A (ja) * | 2013-04-01 | 2014-10-27 | テルモ株式会社 | 生体内物質検出装置 |
US9952033B2 (en) | 2014-02-14 | 2018-04-24 | Palo Alto Research Center Incorporated | Spatial modulation of light to determine object length |
US9528925B2 (en) * | 2014-02-14 | 2016-12-27 | Palo Alto Research Center Incorporated | Spatial modulation of light to determine object position |
US10451482B2 (en) | 2014-02-14 | 2019-10-22 | Palo Alto Research Center Incorporated | Determination of color characteristics of objects using spatially modulated light |
US9400174B2 (en) | 2014-04-07 | 2016-07-26 | Palo Alto Research Center Incorporated | Monitor for particle injector |
WO2018065547A1 (en) * | 2016-10-06 | 2018-04-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Device for monitoring the density of a sample and associated method |
US11703388B2 (en) | 2017-01-19 | 2023-07-18 | Agilent Technologies, Inc. | Optical spectrometer modules, systems and methods for optical analysis with multiple light beams |
US20180303388A1 (en) * | 2017-03-06 | 2018-10-25 | Medtronic Minimed, Inc. | Colorometric sensor for the non-invasive screening of glucose in sweat in pre and type 2 diabetes |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4448534A (en) * | 1978-03-30 | 1984-05-15 | American Hospital Corporation | Antibiotic susceptibility testing |
US6256522B1 (en) * | 1992-11-23 | 2001-07-03 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Sensors for continuous monitoring of biochemicals and related method |
US5560356A (en) | 1994-02-23 | 1996-10-01 | Vitrophage, Inc. | Diagnostic system and method using an implanted reflective device |
PT1108207E (pt) * | 1998-08-26 | 2008-08-06 | Sensors For Med & Science Inc | Dispositivos de sensores ópticos |
EP1251772B1 (en) | 1999-12-22 | 2012-11-14 | Orsense Ltd. | A method of optical measurements for determining various parameters of the patient's blood |
US6383767B1 (en) * | 2000-01-21 | 2002-05-07 | Motorola, Inc. | Luminescent in vivo glucose measurement |
US6952603B2 (en) | 2001-03-16 | 2005-10-04 | Roche Diagnostics Operations, Inc. | Subcutaneous analyte sensor |
US7135342B2 (en) * | 2001-05-04 | 2006-11-14 | Sensors For Medicine And Science, Inc. | Electro-optical sensing device with reference channel |
US7226414B2 (en) | 2002-10-09 | 2007-06-05 | Biotex, Inc. | Method and apparatus for analyte sensing |
US7236812B1 (en) | 2003-09-02 | 2007-06-26 | Biotex, Inc. | System, device and method for determining the concentration of an analyte |
US7254429B2 (en) | 2004-08-11 | 2007-08-07 | Glucolight Corporation | Method and apparatus for monitoring glucose levels in a biological tissue |
US7291824B2 (en) | 2005-12-22 | 2007-11-06 | Palo Alto Research Center Incorporated | Photosensing throughout energy range and in subranges |
US7358476B2 (en) | 2005-12-22 | 2008-04-15 | Palo Alto Research Center Incorporated | Sensing photons from objects in channels |
US7433552B2 (en) | 2005-12-22 | 2008-10-07 | Palo Alto Research Center Incorporated | Obtaining analyte information |
US7545513B2 (en) | 2007-02-05 | 2009-06-09 | Palo Alto Research Center Incorporated | Encoding optical cavity output light |
US7936463B2 (en) | 2007-02-05 | 2011-05-03 | Palo Alto Research Center Incorporated | Containing analyte in optical cavity structures |
US7502123B2 (en) | 2007-02-05 | 2009-03-10 | Palo Alto Research Center Incorporated | Obtaining information from optical cavity output light |
US7471399B2 (en) | 2007-02-05 | 2008-12-30 | Palo Alto Research Center Incorporated | Photosensing optical cavity output light |
US7852490B2 (en) | 2007-02-05 | 2010-12-14 | Palo Alto Research Center Incorporated | Implanting optical cavity structures |
US8320983B2 (en) * | 2007-12-17 | 2012-11-27 | Palo Alto Research Center Incorporated | Controlling transfer of objects affecting optical characteristics |
JP2009191149A (ja) * | 2008-02-14 | 2009-08-27 | Soken Chem & Eng Co Ltd | 偏光板用粘着剤組成物およびこれを利用した偏光板 |
-
2008
- 2008-08-21 US US12/195,997 patent/US7961326B2/en not_active Expired - Fee Related
-
2009
- 2009-08-14 JP JP2009187909A patent/JP5571336B2/ja not_active Expired - Fee Related
- 2009-08-17 EP EP09167957.1A patent/EP2156787B1/en not_active Not-in-force
Also Published As
Publication number | Publication date |
---|---|
EP2156787B1 (en) | 2015-11-04 |
US20100045993A1 (en) | 2010-02-25 |
JP2010048807A (ja) | 2010-03-04 |
EP2156787A1 (en) | 2010-02-24 |
US7961326B2 (en) | 2011-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5571336B2 (ja) | 流体内検体濃度検知方法 | |
JP5421027B2 (ja) | 流体内検体濃度検知システム | |
EP2753918B1 (en) | Optical glucose sensor | |
JP5373379B2 (ja) | 移植可能製品 | |
US8700115B2 (en) | Optical sensor configuration for ratiometric correction of glucose measurement | |
US20100160749A1 (en) | Implantable optical glucose sensing | |
JP3692116B2 (ja) | 皮下検体センサ | |
US5342789A (en) | Method and device for detecting and quantifying glucose in body fluids | |
US20150080685A1 (en) | Equilibrium non-consuming fluorescence sensor for real time intravascular glucose measurement | |
AU2008213677A1 (en) | Optical systems and methods for rationmetric measurement of blood glucose concentration | |
Qu et al. | Monte Carlo modeling studies of the effect of physiological factors andother analytes on the determination of glucose concentration in vivoby near infrared optical absorption and scattering measurements | |
JP2010048807A5 (ja) | 流体内検体濃度検知方法 | |
Rolinski et al. | A time-resolved near-infrared fluorescence assay for glucose: opportunities for trans-dermal sensing | |
WO2015078783A1 (en) | Sensing of components in liquids | |
Ouiganon et al. | An application of optical coherence tomography and a smart polymer gel to construct an enzyme-free sugar sensor | |
Galanzha et al. | Application of optical coherence tomography for diagnosis and measurements of glycated hemoglobin | |
Aloraefy et al. | Development and testing of a fluorescence biosensor for glucose sensing | |
Elsherif | Optical biosensors | |
Martini et al. | Glucose concentration monitoring using a small Fabry-Pérot etalon | |
Yetisen et al. | Article type: Communication | |
Stein | Fluorescent enzymatic smart tattoos comprising hybrid silicate microparticles, metalloporphyrin complexes, and mass transport-limiting nanofilms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120810 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120810 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130830 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130903 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131202 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131205 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131225 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140130 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140603 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140626 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5571336 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |